Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- COVID-19 Antibody Cocktail Ronapreve Faces Tight Manufacturing Capacity Worldwide: Chugai Chairman
September 22, 2021
- New Heart Failure Drugs Jostling with Different Modes of Action, Offering Variety of Options
September 21, 2021
- Takeda to Offload Non-Core Assets in Latin America to Adium
September 21, 2021
- Takeda, Janssen to Wind Up Reminyl Collaboration in Japan
September 21, 2021
- New Probe Finds No Safety Issues with White Matter Detected in Pfizer Jab
September 21, 2021
- Enhertu Enters Chinese PII Study for 3rd Line Gastric Cancer
September 21, 2021
- World’s First CAR-T Clinical Trial for GM2 Solid Cancers Might Begin by Year-End
September 17, 2021
- Sumitomo Dainippon Expects Twymeeg’s Initial Uptake in Combo, but Eyes 1st Line Monotherapy Use Too
September 17, 2021
- EA Pharma Appoints Eisai Senior VP Hidenori Yabune as President
September 17, 2021
- Takeda’s Exkivity Gets US Nod for EGFR Exon 20-Mutant NSCLC
September 17, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- White Matter Found in COVID-19 Vaccine Vials Not Contaminant: Pfizer
September 16, 2021
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Another Patient Dies in Astellas’ Gene Therapy Trial, FDA Issues New Clinical Hold
September 15, 2021
- Taiho Seeks Japan Approval for GIST Drug Pimitespib
September 15, 2021
- Keytruda Filed for RCC Adjuvant Therapy in Japan: MSD
September 15, 2021
- Kyowa Kirin’s G-Lasta Enters Japan PII Study for Stem Cell Transplant
September 14, 2021
- Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
September 13, 2021
- Choseido’s Cymbalta Generic Now Available in Japan
September 13, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…